ANTX - NASDAQ

AN2 Therapeutics, Inc.

ANTX·NASDAQ

$4.28

+3.9%

HealthcareBiotechnology

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$117.27M

EPS-1.1600

P/E Ratio-3.69

Earnings Date08/06/2026

61.95M

Assets

-33%

3Y-40.0%

5Y+1363.0%

10Y+987.0%

8.89M

Total Liabilities

-13%

3Y+24.0%

5Y+499.0%

10Y+902.0%

53.06M

Total Equity

-35%

3Y-44.0%

5Y+1829.0%

10Y+1002.0%

AN2 Therapeutics, Inc. Funding & Solvency Profile

ANTX · NASDAQ

Current Assets

Cash & Cash Equivalents19.94M

Net Receivables900.00K

Inventory0.00

Other Current Assets1.04M

Total Current Assets60 M

Non-Current Assets

Property, Plant & Equipment0.00

Goodwill & Intangible Assets0.00

Long-Term Investments2.01M

Other Non-Current Assets0.00

Total Non-Current Assets2 M

Total Assets

61.95M

Financial Health Analysis

Current Ratio

6.87x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.17x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

51 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

97% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

AN2 Therapeutics, Inc. Balance Sheet

ANTX • NASDAQ

AN2 Therapeutics, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	19.9M	21.4M	15.6M	27.2M	12.1M	4.1M	5.6M
Short-Term Investments	38.1M	62.3M	91.6M	68.8M	46.5M	0.0	0.0
Cash & Short-Term Investments	58M	83.6M	107.3M	96.1M	58.6M	4.1M	5.6M
Net Receivables	900K	300K	1.4M	0.0	0.0	0.0	0.0
Accounts Receivables	500K	0.0	400K	0.0	0.0	0.0	0.0
Other Receivables	400K	300K	1M	0.0	0.0	0.0	0.0
Prepaids	0.0	0.0	1.8M	0.0	1.6M	164K	20K
Other Current Assets	1M	2.3M	0.0	2.6M	0.0	0.0	82K
Total Current Assets	59.9M	86.3M	110.5M	98.6M	60.1M	4.2M	5.7M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	0.0	0.0	0.0	53K	0.0	0.0	0.0
Long-Term Investments	2M	5M	27.2M	3.2M	3.5M	0.0	0.0
Other Non-Current Assets	0.0	804K	1M	667K	1.7M	0.0	0.0
Total Non-Current Assets	2M	5.8M	28.2M	3.9M	5.2M	0.0	0.0
Total Assets	62M	92.1M	138.7M	102.6M	65.3M	4.2M	5.7M
LIABILITIES
CURRENT LIABILITIES
Total Payables	3M	3.3M	2.7M	2.1M	1.1M	132K	51K
Accounts Payable	3M	3.3M	2.7M	2.1M	1.1M	132K	51K
Accrued Expenses	0.0	4.5M	6.7M	5M	2M	1.3M	108K
Capital Lease Obligations (Current)	0.0	0.0	0.0	53K	0.0	0.0	0.0
Other Current Liabilities	5.7M	2.5M	4.7M	6K	330K	14K	0.0
Total Current Liabilities	8.7M	10.2M	14M	7.2M	3.4M	1.5M	159K
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	0.0	0.0	0.0	0.0	728K
Other Non-Current Liabilities	170K	0.0	0.0	2K	13K	24K	0.0
Total Non-Current Liabilities	170K	0.0	0.0	2K	13K	24K	728K
Capital Lease Obligations	0.0	0.0	0.0	53K	0.0	0.0	0.0
Total Liabilities	8.9M	10.2M	14M	7.2M	3.4M	1.5M	887K
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	109.3M	23.1M	10.6M
Additional Paid-In Capital	294M	287.6M	278.9M	185.5M	0.0	0.0	0.0
Retained Earnings	-241M	-205.8M	-154.5M	-89.7M	-47.4M	-20.3M	-5.8M
Accumulated Other Comprehensive Income/Loss	57K	31K	275K	-374K	-27K	0.0	0.0
Total Stockholders' Equity	53.1M	81.8M	124.7M	95.4M	61.9M	2.8M	4.8M
Total Equity	53.1M	81.8M	124.7M	95.4M	61.9M	2.8M	4.8M
SUMMARY
Total Liabilities & Equity	62M	92.1M	138.7M	102.6M	65.3M	4.2M	5.7M
Total Investments	40.1M	67.3M	118.8M	72.1M	49.9M	0.0	0.0
Total Debt	0.0	0.0	0.0	53K	0.0	0.0	728K
Net Debt	-19.9M	-21.4M	-15.6M	-27.2M	-12.1M	-4.1M	-4.9M
Shares Outstanding	27,402,024	27,402,024	27,402,024	27,402,024	27,402,024	27,402,024	27,402,024

SEC Filings

ANTX - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 11, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 11, 2026	May 11, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 22, 2026	April 22, 2026	2026	View Filing
S-3 S-3 N/A	April 09, 2026	April 09, 2026		View Filing
8-K 8-K 2026 N/A	April 09, 2026	April 09, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 20, 2026	March 19, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 17, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 17, 2026	March 17, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 10, 2026	March 08, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 29, 2026	January 26, 2026	2026	View Filing

Showing 1 to 10 of 63 filings

Related Guides

Blog Categories

Continue your ANTX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.